Related Experiment Videos
Reversible deficient prostacyclin release in childhood hemolytic uremic syndrome
Insights
Plasma from children with acute hemolytic uremic syndrome (HUS) impairs prostacyclin release. This suggests the abnormality is acquired, not congenital, in most HUS cases.
Area of Science:
- Pediatric Nephrology
- Vascular Biology
- Hematology
Background:
- Hemolytic Uremic Syndrome (HUS) is a serious condition affecting children.
- Endothelial dysfunction and impaired prostacyclin release are implicated in HUS pathogenesis.
- The origin of plasma abnormalities in HUS remains unclear.
Purpose of the Study:
- To investigate the effect of plasma from HUS patients on prostacyclin release.
- To determine if the observed plasma abnormality in HUS is congenital or acquired.
Main Methods:
- Plasma samples were collected from infants and children with acute HUS and those in remission.
- The capacity of plasma to stimulate prostacyclin-like activity was assessed using "exhausted" rat aorta rings.
- Statistical analysis was performed to compare groups.
Main Results:
- Plasma from 10 out of 12 children in the acute phase of HUS failed to stimulate prostacyclin release.
- Only 3 out of 15 children in remission showed a similar impairment in prostacyclin release.
- This difference was statistically significant (p < 0.005).
Conclusions:
- A significant plasma abnormality affecting prostacyclin release is present in the acute phase of HUS.
- The findings strongly suggest that this abnormality is acquired during the acute phase of HUS, rather than being a congenital condition.
- This acquired defect may contribute to the pathophysiology of HUS.
Abstract:
Plasma was taken from infants and children with acute hemolytic uremic syndrome (HUS) or following remission from this disease. The capacity of these plasma to stimulate release of prostacyclin-like activity from "exhausted" rat aorta rings was studied. Plasma from 10 out 12 children in the acute phase of HUS, but from only 3 out of 15 children following remission failed to stimulate prostacyclin release (p less than 0.005). These findings suggest that, for the majority of children, the plasma abnormality in the acute phase of the disease is acquired rather than congenital.